Literature DB >> 8113767

Changes in the dominant Epstein-Barr virus type during human immunodeficiency virus infection.

M Buisson1, P Morand, O Genoulaz, M J Bourgeat, M Micoud, J M Seigneurin.   

Abstract

Two types of Epstein-Barr virus (EBV), EBV-1 and EBV-2, were identified on the basis of DNA sequence divergence in the genes for nuclear proteins EBNA 2, 3a, 3b and 3c. In the present study, we conducted an immunological and genomic analysis in a human immunodeficiency virus (HIV)-infected population to determine the prevalence of the two types, and whether the identified type was stable over years. The EBNA-2 serotyping and genotyping showed that HIV-infected patients were highly infected by EBV-2, and that the dominant strain was mostly retained. However, during a follow-up study, a change in the dominant viral strain was observed in two patients. A first HIV-positive patient (patient A), although having a stable level of anti-EBNA-2A and -2B antibodies, showed a change in the genotype and antigen produced in spontaneously established lymphoblastoid cell lines (LCL). The sequence analysis of LCLs confirmed the emergence of the EBV-2 type population. A strain from a second HIV-positive patient (patient B) was clearly identified as EBV-2: the genotype from a saliva sample and from sequential LCLs belonged to EBV-2, as well as the antigen produced from LCLs, and serum antibodies. After a 5-year continuous EBV-2 infection, a reactivation of the EBV-1 strain was observed. In both cases, sequence analysis of the EBNA-2 gene showed, only with EBV-1, the presence of EBV variants related to the B95-8 prototype. Two mutations (at nucleotides 49212 and 49304) were found in both patients A and B, whereas an additional mutation (at nucleotide 49237) was characteristic of the patient A. No mutation relative to the prototype B95-8 strain was observed in a subsequent analysis of this EBNA-2 region from LCLs obtained from two HIV-negative patients predominantly infected by EBV-1. Therefore, we speculate that these mutations may be EBV-1 mutations specifically occurring during HIV infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8113767     DOI: 10.1099/0022-1317-75-2-431

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

1.  Epstein-Barr virus recombinants from BC-1 and BC-2 can immortalize human primary B lymphocytes with different levels of efficiency and in the absence of coinfection by Kaposi's sarcoma-associated herpesvirus.

Authors:  A J Aguirre; E S Robertson
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Novel intertypic recombinants of epstein-barr virus in the chinese population.

Authors:  R S Midgley; N W Blake; Q Y Yao; D Croom-Carter; S T Cheung; S F Leung; A T Chan; P J Johnson; D Huang; A B Rickinson; S P Lee
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Epidemiology of infection with Epstein-Barr virus types 1 and 2: lessons from the study of a T-cell-immunocompromised hemophilic cohort.

Authors:  Q Y Yao; D S Croom-Carter; R J Tierney; G Habeshaw; J T Wilde; F G Hill; C Conlon; A B Rickinson
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Identification of a naturally occurring recombinant Epstein-Barr virus isolate from New Guinea that encodes both type 1 and type 2 nuclear antigen sequences.

Authors:  J M Burrows; R Khanna; T B Sculley; M P Alpers; D J Moss; S R Burrows
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

5.  Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus.

Authors:  B M Kerr; N Kienzle; J M Burrows; S Cross; S L Silins; M Buck; E M Benson; B Coupar; D J Moss; T B Sculley
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

6.  Cytotoxic T-lymphocyte responses to a polymorphic Epstein-Barr virus epitope identify healthy carriers with coresident viral strains.

Authors:  J M Brooks; D S Croom-Carter; A M Leese; R J Tierney; G Habeshaw; A B Rickinson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

7.  Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals.

Authors:  Q Y Yao; R J Tierney; D Croom-Carter; D Dukers; G M Cooper; C J Ellis; M Rowe; A B Rickinson
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

8.  Prediction of MicroRNAs in the Epstein-Barr Virus Reveals Potential Targets for the Viral Self-Regulation.

Authors:  Victor Serrano-Solis; Angelica Cardoso Carlos; Vinicius Maracaja-Coutinho; Sávio Torres de Farias
Journal:  Indian J Microbiol       Date:  2018-12-28       Impact factor: 2.461

9.  Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas.

Authors:  F Fina; S Romain; L Ouafik; J Palmari; F Ben Ayed; S Benharkat; P Bonnier; F Spyratos; J A Foekens; C Rose; M Buisson; H Gérard; M O Reymond; J M Seigneurin; P M Martin
Journal:  Br J Cancer       Date:  2001-03-23       Impact factor: 7.640

10.  EBV-positive diffuse large B-cell lymphoma in a human T-lymphotropic virus type 1 carrier.

Authors:  Brady Beltran; Renzo Salas; Pilar Quiñones; Domingo Morales; Fernando Hurtado; Esther Cotrina; Luis Riva; Jorge Castillo
Journal:  Infect Agent Cancer       Date:  2009-07-06       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.